

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

NCT06174220

Status	RECRUITING
Phase	Phase 2
Sponsor	Hamilton Health Sciences Corporation
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (4)

- A pathogenic or likely pathogenic desmosomal (PKP2, DSG2, DSC2, DSP, or JUP^{*}) rare variant OR the TMEM43-p.S358L variant
- ^{*}JUP carriers must be homozygous or compound heterozygous
- Mean \leq 500 PVCs per 24 hours on a baseline screening 7-day Holter monitor
- Clinical ACM diagnosis or recognition of genetic carrier status for \geq 6 months prior to screening

Exclusion (14)

- NYHA class IV heart failure
- Ventricular scar secondary to coronary artery disease
- Initiation, cessation, or dose change of a Class I or III anti-arrhythmic drug in the 3 months prior to screening
- Any potentially harmful chronic liver disease
- ALT value $>$ 2X the upper limit of the normal reference range at Screening
- ... and 9 more (see full listing online)

Locations (17 total)

University of Calgary, Calgary, Alberta, Canada
University of British Columbia, Vancouver, British Columbia, Canada
Victoria Cardiac Arrhythmia Trials Inc., Victoria, British Columbia, Canada
... and 14 more locations